minocycline / Generic mfg. - LARVOL DELTA

Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials (AAD 2026) - "Background: We compared the efficacy of a modified low-dose formulation of minocycline hydrochloride 40 mg (DFD-29), doxycycline 40 mg, and placebo in participants with moderate versus severe rosacea. There were no clinically meaningful differences in DFD-29 efficacy by baseline rosacea severity and the efficacy of DFD-29 was greater than that of doxycycline and placebo in all subgroups."

Clinical • P3 data • Dermatology • Rosacea

Association Between Biologic Therapy and Acne Treatment Escalation Among Patients with Inflammatory Acne: A TriNetX Database Study (AAD 2026) - "Risk ratios (RRs) of systemic acne therapy (doxycycline, minocycline, sarecycline, spironolactone, or isotretinoin) were calculated. This may be attributable to further Th1/Th17 skewing as a result of biologic therapy, thereby exacerbating immune dysregulation and rendering patients refractory to topical treatments. Further studies are warranted to clarify the clinical significance and mechanistic basis of these findings."

Clinical • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Immunology • Psoriasis

Post-Isotretinoin Acne Management: A Survey of Dermatology Practitioners (AAD 2026) - "Topical retinoids and benzoyl peroxide were utilized in mild and moderate relapse, with the addition of spironolactone for females (53.1%) and doxycycline/minocycline for males (61%) in moderate cases. The variability in recommendations highlights the need for evidence-based post-isotretinoin guidelines and increased awareness of relapse risk to optimize care and reduce repeat isotretinoin therapy."

Acne Vulgaris • Dermatology

Insurance Coverage of Rosacea Topicals: A Cross-Sectional Review (AAD 2026) - " Azelaic acid gel, oxymetazoline hydrochloride cream, ivermectin cream, sulfacetamide sodium–sulfur cleanser, metronidazole gel, minocycline foam, brimonidine gel, and Epsolay benzoyl peroxide (BPO) cream were reviewed across UnitedHealth Group, Elevance (Anthem), CVS Health (Aetna), Cigna, Health Care Service Corporation Blue Cross Blue Shield (BCBS), Kaiser Permanente, BCBS Florida, BCBS Michigan, Centene, and Blue Shield of California. Only two rosacea topicals were consistently covered by major commercial insurers, and many plans imposed quantity limits and step therapy barriers. Interestingly, metronidazole, identified as less effective than the uncovered topicals, was the most covered agent. [5] This disconnect between evidence-based rosacea treatments and insurer restrictions underscores the need for reform and improved access."

Reimbursement • Review • US reimbursement • Dermatology • Inflammation • Rosacea

Isotretinoin and Psychiatric Risk in Transgender Patients: A Retrospective Cohort Study (AAD 2026) - "Exposures: isotretinoin vs topical monotherapy (clindamycin, benzoyl peroxide, adapalene, tretinoin) or oral antibiotics (doxycycline, minocycline). Given the high baseline psychiatric risk in this population, proactive mental health screening during acne treatment is warranted. Larger prospective studies are needed to clarify causality and inform risk mitigation."

Retrospective data • Acne Vulgaris • CNS Disorders • Depression • Mood Disorders • Psychiatry

Minocycline-Induced Microscopic Polyangiitis with Necrotizing Myopathy and Severe Multiorgan Involvement (AAD 2026) - No abstract available

Myositis

DRESS With Distress: Minocycline-Induced Multisystem Drug Reaction in a Pediatric Patient (AAD 2026) - No abstract available

Clinical • Pediatrics

Elizabethkingia Species as an Emerging Pathogen: A Comprehensive Review of Clinical and Microbiological Evidence. (PubMed, Pathogens) - "Across studies, isolates showed broad resistance to β-lactams and near-universal resistance to carbapenems, with variable activity to fluoroquinolones and trimethoprim-sulfamethoxazole and more consistent in vitro activity to minocycline. Species misidentification (notably Elizabethkingia anophelis as Elizabethkingia meningoseptica) and heterogeneous susceptibility testing limited comparability. Outbreak investigations repeatedly implicated water-associated reservoirs and reusable equipment, underscoring the need for improved diagnostics, susceptibility-guided therapy and water-focused infection prevention."

Journal • Review • CNS Disorders • Critical care • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases • Septic Shock

Clonal Dynamics and Antimicrobial Resistance of Bloodstream Carbapenem-Resistant Acinetobacter baumannii Isolates from Korean Hospitals Between 2016 and 2020. (PubMed, Antibiotics (Basel)) - "Resistance rates were ≥80% for ampicillin-sulbactam and ciprofloxacin...ST195 exhibited higher resistance to minocycline (29.4%) than did the other STs. Dynamic clonal shifts and high antimicrobial resistance exist among CRAB isolates in Korean hospitals, with the rapid emergence of ST195 and ST369 increasing clinical challenges. Continuous epidemiological surveillance and targeted infection control measures are essential to control the spread of high-risk CRAB clones."

Journal • Infectious Disease

Disequilibrium, Rather than Postural Orthostatic Tachycardia Syndrome, Is the Primary Determinant of Orthostatic Intolerance in Patients with Long COVID. (PubMed, J Clin Med) - "After 6 weeks of oral minocycline treatment in six patients and 2 weeks of repetitive transcranial magnetic stimulation therapy following minocycline in the other one patient, symptom amelioration was reported in six patients with OI. OI concomitant with disequilibrium recovered in five of the six patients treated and tested, although one patient who experienced symptom recovery failed to undergo the repeated standing test. Disequilibrium, rather than POTS, was the primary determinant of OI in patients with long COVID."

Journal • Cardiovascular • CNS Disorders • Novel Coronavirus Disease

T-2 Toxin Neurotoxicity: Molecular Mechanisms and Emerging Chemoprotective Strategies. (PubMed, Antioxidants (Basel)) - "Additionally, it was reported that several antioxidants, small inhibitors and nature products, such as daucosterol, betulinic acid, AHN 1-055 hydrochloride, dimethyl fumarate and minocycline supplementations, can partly ameliorate these harmful effects. This review provides valuable insights into the underlying mechanisms of T-2 toxin-induced neurotoxicity and novel effective detoxification strategies."

Journal • Review • Inflammation • Metabolic Disorders • BTG2 • HIF1A • HMGB1

Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review. (PubMed, Infect Dis Ther) - "Tetracyclines may provide therapeutic options for refractory or MDR-related BJIs, and for suppressive therapy when surgical or antibiotic alternatives are limited. However, available data are heterogeneous and largely observational. Robust prospective studies are needed to clarify their role, particularly for newer agents such as omadacycline and eravacycline."

Journal • Review • Infectious Disease • Inflammation

Environmental triggers of autoimmune hepatitis: a clinical perspective from Yemeni patients. (PubMed, Front Immunol) - "Exposure to medications known to induce autoimmune reactions, such as nitrofurantoin and minocycline, was also higher among patients (27.9% versus 1.8%, OR: 21.3; 95% CI: 7.9-57.7, p < 0.001). These findings highlight the important role of environmental factors, particularly Khat chewing and pesticide exposure, in the development and progression of autoimmune hepatitis in Yemen. Public health interventions addressing these exposures may help reduce disease burden."

Journal • Autoimmune Hepatitis • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - P4 | N=480 | Completed | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Completed | Trial completion date: Aug 2026 ➔ Feb 2026 | Trial primary completion date: Aug 2026 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

EFFICACY OF DAPTOMYCIN FOR VANCOMYCIN-REFRACTORY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS SEPSIS ASSOCIATED WITH VENOUS HYPERTENSION IN VASCULAR ACCESS -A CASE REPORT- (ISN-WCN 2026) - "Therefore, the antibiotic was changed to DAP and rifampicin (RFP) was administered in combination...After switching to oral minocycline (MINO), there was no relapse, and the patient was discharged five months after admission...Venous hypertension and skin erosion in the VA were suspected as causes of MRSA sepsis. Since changes in central venous patency may occur after major vascular surgery, careful consideration is required for the location of VA creation.Conclusion These results indicate that DAP may be an effective treatment option for VCM-resistant MRSA sepsis associated with artificial materials."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Hypertension • Infectious Disease • Inflammation • Nephrology • Pulmonary Embolism • Respiratory Diseases • Septic Shock

CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME TRIGGERED BY BULLOUS PEMPHIGOID: A CASE REPORT (ISN-WCN 2026) - "Renal biopsy and positive antiphospholipid antibodies confirmed primary APS, and plasma exchange, corticosteroids, warfarin, and antiplatelet therapy improved renal function from a serum creatinine level of 4.0 mg/dL to 2.0 mg/dL with long-term stability.Five months before admission, he developed generalized bullae and was diagnosed with BP based on an elevated BP180 antibody titer (5760 U/mL). The lesions improved with minocycline, nicotinamide, and prednisolone, and the antibody titer decreased to 1200 U/mL...He was hospitalized and treated with vancomycin, meropenem, intravenous immunoglobulin, and methylprednisolone (40 mg/day), which led to temporary improvement.Results On hospital day 14, inflammation worsened again, accompanied by melena and coagulopathy with a prolonged PT-INR...Autopsy revealed widespread thrombi not only in the gastrointestinal tract but also in multiple systemic organs, leading to the diagnosis of catastrophic antiphospholipid syndrome (CAPS)..."

Case report • Clinical • Bullous Pemphigoid • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Dermatology • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Inflammation • Nephrology • Peptic Ulcer • Renal Disease • Thrombosis

Decoding Carbapenem Resistance: Detection of Carbapenemase Genes in Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii. (PubMed, Cureus) - "The highest sensitivity was observed for minocycline (15/100, 15%), followed by cotrimoxazole. The coexistence of multiple carbapenemase genes, including bla NDM-1, bla OXA-23, and bla VIM, reflects significant genetic diversity and enhances the potential for horizontal gene transfer and rapid dissemination within healthcare settings. Such high-level gene coexistence has important clinical and epidemiological implications, as it may contribute to treatment failure and hospital outbreaks. This finding emphasizes the critical need for strict infection control measures, antimicrobial stewardship programs, and continuous molecular surveillance of resistance determinants to limit the spread of these MDR organisms."

Journal • Gene Therapies • Infectious Disease

The ICU environment paradigm as a strategy to enhance the validity of delirium animal models. (PubMed, Clin Sci (Lond)) - "In sepsis + ICU, minocycline and dexmedetomidine reduced IL-1β/IL-6 and improved behavioral performance; rivastigmine improved selected behavioral domains, increased acetylcholine, and reduced AChE activity; dexmedetomidine decreased ROS; and minocycline and rivastigmine attenuated microgliosis. The ICU-like environment worsened behavioral and neurochemical changes, surgery plus anesthesia, and sepsis, supporting its value for enhancing model validity."

Journal • Preclinical • Anesthesia • CNS Disorders • Infectious Disease • Inflammation • Pain • Septic Shock • IL1B • IL6

Two-week course of minocycline therapy for early syphilis compared with benzathine penicillin G: a single-centre retrospective cohort study. (PubMed, Sex Transm Infect) - No abstract available

Journal • Retrospective data • Infectious Disease

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. (PubMed, J Thorac Oncol) - P2 | "An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Targeting the oxidative stress-neuroinflammation axis: the mechanism of arctigenin's broad-spectrum analgesia with limited side effects. (PubMed, Front Immunol) - "Meanwhile, we found that pretreatment with the U0126 or SB203580 or SP600125, 30 min prior to AG administration, blocked the analgesic effects of AG in SNI mice...pretreating with minocycline reduced but did not completely block the analgesic effect of AG, indicating that the activation of spinal cord microglia is not necessary for the antiallodynic effect of AG...Concurrently, studies on short-term toxic side effects revealed that prolonged AG injection had no impact on hepatic or renal functions and produced none of the typical analgesic side effects, including tolerance, addiction, or constipation, indicating limited antinociceptive side effect. The present study is the first to provide evidences that AG may represent a novel therapeutic target with high analgesic activity and low side effects for the treatment of neuropathic pain."

Adverse events • Journal • CNS Disorders • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Inflammation • Metabolic Disorders • Neuralgia • Pain • Psychiatry • Type 2 Diabetes Mellitus

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). (PubMed, Microbiol Spectr) - "This study aims to evaluate the in vitro activity of sulbactam-durlobactam and comparator antibiotics, including meropenem and cefiderocol against A. baumannii-calcoaceticus complex isolates from non-respiratory and non-bloodstream sources...Minocycline susceptibility was 69.1%, while tigecycline and eravacycline MICs50/90 were 1/4 and 0.5/1 mg/L, respectively...The results are important because they can inform clinicians on the susceptibility profiles of A. baumannii from a variety of infection sources, not just lung and bloodstream. As new antibiotics come onto the market, it is important to continuously assess resistance patterns to inform patient and system-wide health decisions."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Innovative murine survival pulmonary model for ESKAPE isolates, assessing virulence and cefiderocol and minocycline efficacy (ESCMID Global 2026) - No abstract available

Preclinical

Efficacy of minocycline-based combination therapy in Stenotrophomonas maltophilia infections from a randomised controlled trial, and the activity of antimicrobial combinations against isolates as determined by the checkerboard method (ESCMID Global 2026) - No abstract available

Clinical • Combination therapy • Infectious Disease

Efficacy of Minocycline in Acute Traumatic Spinal Cord Injury. (PubMed, J Neurotrauma) - "Minocycline, a tetracycline antibiotic with anti-inflammatory and neuroprotective properties, has been proposed as a therapeutic candidate...In humans, intravenous minocycline (200-400 mg daily for 7 days) achieved cerebrospinal fluid concentrations of ∼2.3 µg/mL, below the therapeutic range suggested by preclinical models (35-75 µg/mL)...Overall, minocycline exerts robust neuroprotective effects in preclinical SCI but limited functional benefit in humans, largely due to subtherapeutic central nervous system penetration at tolerated systemic doses. Future trials should explore optimized delivery strategies, include demographic stratification, and employ standardized functional endpoints to better define translational potential."

Journal • CNS Disorders • Orthopedics